Cardiovascular Medicine
Research activity is centered on heart failure with preserved ejection fraction, with attention to the clinical features and cardiovascular burden of this condition.
- Heart failure with preserved ejection fraction
- Cardiac function
- Cardiovascular disease
The sponsor’s funded work in this area reflects a focused interest in conditions where symptoms of heart failure occur despite maintained left ventricular ejection fraction.
Metabolic-Cardiac Interactions
Its clinical research includes the relationship between sodium-glucose cotransporter 2 inhibition and cardiovascular outcomes in patients with heart failure.
- SGLT2 inhibition
- Cardiometabolic disease
- Glucose transport pathways
This area connects metabolic regulation with cardiac performance, highlighting interest in therapies relevant to both metabolic and cardiovascular domains.
Biological Mechanisms
The funded trial is directed toward understanding the biological mechanisms underlying the cardiovascular effects observed in ICFEP.
- Mechanistic biology
- Pathophysiology
- Cardiovascular remodeling
Work in this domain focuses on how treatment-related effects relate to disease biology in preserved ejection fraction heart failure.
Biomechanics
Another key interest is the biomechanical mechanisms associated with cardiovascular benefit in heart failure with preserved ejection fraction.
- Biomechanical function
- Hemodynamic regulation
- Myocardial mechanics
This includes investigation of structural and functional aspects of the heart that may influence symptom development and treatment response.
